Thus, our results suggest that treatment of tumor-bearing mice with DMXAA enhances the systemic E7-specific CD8+ T cell immune responses and antitumor effects generated by CRT/E7 DNA vaccination. The gene discussed is CD8A; the disease is neoplasm.